Navigation Links
Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients

MOUNTAIN VIEW, Calif., Feb. 19 /PRNewswire/ -- Based on its recent analysis of the North American health ingredients market, Frost & Sullivan recognizes Horphag Research Ltd. with the 2008 North American Frost & Sullivan Excellence in Research of the Year Award. The award acknowledges the company's extensive research projects and numerous clinical tests, spread over 40 years, aimed at validating the health benefits of the ingredient, Pycnogenol(R), across industries such as food and beverage ingredients and pharmaceuticals.


"Pycnogenol(R) is one of the most evidence-based health ingredients with over 220 scientific publications and 80 clinical trials on 7000 patients, confirming its safety, non toxicity, and clinical efficacy since 1975," says Frost & Sullivan Research Analyst Sneha Pasricha. "The published studies have validated Pycnogenol(R)'s role in promoting a wide range of health benefits including cardiovascular, circulatory, cognitive, diabetes, eye, skin, and joint health."

A study in 1975 confirmed Pycnogenol(R)'s potential to reduce edema and pain in the lower legs, while another one in 1986 corroborated Pycnogenol(R)'s protective effects on the eyes. In 1998, numerous studies proved Pycnogenol(R)'s beneficial role in cardiovascular health and normalization of platelet function.

Several studies conducted in 2004 revealed Pycnogenol(R)'s ability to lower blood glucose levels and improve metabolic syndrome and diabetic complications. In 2006, evidence was obtained regarding Pycnogenol(R)'s anti-inflammatory potency in humans that causes relief during menstrual pain and asthma. A series of research efforts in 2008 validated Pycnogenol(R)'s capability to reduce pain and improve joint flexibility in osteoarthritis patients.

"Horphag has 12 ongoing research works on Pycnogenol(R) in the pipeline and in December 2008, another study was published, demonstrating significant lowering of the inflammatory marker, C-reactive protein (CRP) in osteoarthritis patients post intake of Pycnogenol(R)," notes Pasricha. "These key research initiatives demonstrate the company's accomplishments that have surpassed all similar efforts undertaken by other research institutes on Pycnogenol(R)."

Pycnogenol(R)'s versatility is obvious in its capacity to not only improve blood flow, blood lipid profile, and strengthening blood capillary walls but also to lower cholesterol, normalize blood pressure, and prevent thrombosis. It reduces blood glucose level and carbohydrate absorption, thereby preventing diabetic syndrome, diabetic ulcers, and muscle cramps.

Its antioxidant properties and anti photo-aging potencies make it ideal for oral and topical skin care formulas, while its capability to bind collagen and elastin improves skin elasticity and reduces pigmentation. Its immune modulation profile makes it suitable for combating asthma and hay fever, thereby promoting respiratory health.

Evidently, Pycnogenol(R) provides a reliable and clinically tested nutritional option of addressing a comprehensive range of health issues across the food and beverage ingredients and pharmaceutical industries. Moreover, it is one of the few ingredients that conform to bioavailability, metabolization, excretion, and complete pharmacokinetics in humans.

"Pycnogenol(R) has set a new benchmark for all nutritional ingredients and dietary supplements in terms of its versatile health benefits, safety data, and research portfolio and has the highest probability of becoming an undisputed industry standard in the near future," observes Pasricha. "In addition, Pycnogenol(R) has received Kosher certification for quality and generally recognized as safe (GRAS) approval for use in functional foods in 2003."

Pycnogenol(R) is protected by U.S. and international patents. It received the U.S. patent 5,720,956 in 1998, which states the potency of Pycnogenol(R) to inhibit platelet aggregation induced by cigarette smoking without hampering the bleeding time that is characteristic of aspirin usage. Horphag was also awarded the U.S. patent 6,372,266 on Pycnogenol(R) for its ability to reduce pain and discomfort during menstruation.

These patents, along with various publications of scientific studies, clinical tests, and peer-reviewed journals on Pycnogenol(R) provide a range of intellectual property rights for Horphag.

Each year, Frost & Sullivan presents this award to the company that has carried out new 'disruptive' research. This award recognizes a company's R&D program that has or is expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The fruits of this research may already have or will potentially impact certain market sectors. The award also recognizes the company's overall research excellence as well as its commitment toward differentiating itself based on science-backed services or solutions.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Horphag Research Ltd.

Horphag Research is the exclusive worldwide supplier of Pycnogenol(R) French maritime pine bark extract. Founded in Berlin in 1925, Horphag Research is a leading company supplying fortifying nutritional products and is a pioneer in the natural products industry. Over the last forty years, the company has invested in extensive scientific research and today Pycnogenol(R) is one of the most evidence-based health ingredients in the industry with over 220 scientific publications confirming its safety, non toxicity and clinical efficacy. Pycnogenol(R) is a registered trademark of Horphag Research Ltd.; Guernsey and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. Keeping in line with our commitment to science and innovation, comprehensive research and development programs continue to be carried out and new health applications for Pycnogenol(R) are explored every year in the fields of nutraceuticals, cosmeceuticals and functional foods and beverages. For more information about Pycnogenol(R) visit our Web site at

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

    Jake Wengroff

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
2. Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation
3. Frost & Sullivan Says, Innovative Therapies Needed to Deal With the Rapid Spread of Cancer in Europe
4. Frost & Sullivan Helps You Know Your End-Market: Medical Trends Impacting the Chemicals and Materials Markets
5. Frost & Sullivan - Consumer Preference for Healthy Bakery
6. Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom
7. Frost & Sullivan Bestows Product Line Strategy Leadership Award to VTS Medical Systems, LLC
8. Frost & Sullivan Forecasts Increased Demand for Portable and PC-based Ultrasound Units in Eastern Europe
9. Verified Physicians a Must for Ensuring Quality Data From Online Surveys, Finds Frost & Sullivan
10. Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
11. Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?
Post Your Comments:
(Date:11/25/2015)... Ill. (PRWEB) , ... November 25, 2015 , ... ... and potentially more aggressive than those found on mammography, according to a study ... findings of additional cancers not seen on mammography may necessitate a change in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... factory direct sauna parts and accessories. , Sauna accessories help improve the bather ... style and personality. From basic styles for the purist looking for simplicity in ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced musical show, ... 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for this final ... has been a treasured tradition for numerous families in the Evanston community. Over ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
(Date:11/25/2015)... --> --> ... was valued at $11,171.1 million in 2014, and it ... during 2015 - 2022. The global market is growing, ... diabetes. In addition, the increase in obese population and ... the growth of the market. Furthermore, technological advancements in ...
Breaking Medicine Technology: